FDA Approves Natesto Nasal Spray To Treat Men With Low Testosterone

Trimel Pharmaceuticals Corp. May 28 announced that the Food and Drug Administration has approved Natesto (testosterone), the first testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Natesto is self-administered via a nasal applicator, thereby minimizing the risk of secondary exposure to testosterone for women or children, the company said.

It is conservatively estimated that nearly 13 million American men may have low testosterone levels, Trimel said. Current treatment focuses on restoring the physiological testosterone level through the use of exogenous testosterone preparations, which include topical gels applied by ...